Clik here to view.
Bevacizumab significantly improves survival for patients with recurrent and...
Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did...
View ArticleClik here to view.
NIH trial shows promising results in treating a lymphoma in young people
Patients with a type of cancer known as primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to an area of the thorax known as the...
View ArticleClik here to view.
NIH-funded study shows increased survival in men with metastatic prostate...
Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy...
View ArticleClik here to view.
New treatment option for young women with hormone-sensitive breast cancer
A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also...
View Article
